Motley Fool Asset Management LLC Purchases 82,975 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Motley Fool Asset Management LLC raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 98.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,448 shares of the biopharmaceutical company’s stock after acquiring an additional 82,975 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $6,088,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Fred Alger Management LLC boosted its position in Ultragenyx Pharmaceutical by 12.5% during the first quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company’s stock valued at $18,997,000 after acquiring an additional 58,372 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $353,000. Assenagon Asset Management S.A. boosted its position in shares of Ultragenyx Pharmaceutical by 439.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock worth $42,314,000 after purchasing an additional 947,865 shares in the last quarter. Millennium Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 2.2% during the 1st quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company’s stock worth $25,796,000 after purchasing an additional 15,157 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Ultragenyx Pharmaceutical by 59.8% during the 2nd quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company’s stock worth $2,208,000 after purchasing an additional 22,509 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $35.31 on Tuesday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $55.06. The firm has a market capitalization of $3.40 billion, a PE ratio of -6.39 and a beta of 0.21. The company’s 50-day moving average is $30.84 and its 200 day moving average is $32.95.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. The company had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm’s revenue was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on RARE shares. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They set an “overweight” rating and a $65.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $82.27.

Insider Activity

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Howard Horn sold 7,942 shares of the stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,456 shares of company stock valued at $328,486. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.